Adastra Expands Market Footprint Through Receipt of Medical Sales License from Health Canada
August 17, 2022
Ryan Allway August 17th, 2022 News, Top News LANGLEY, BC / ACCESSWIRE / August 17, 2022 / Adastra Holdings Ltd. (CSE:XTRX)(FRA:D2EP) (“Adastra” or the “Company”), a leading cannabis company focused on processing, product development, sales, organoleptic testing and analytical testing, is pleased to announce it has received its Medical Sales... Read more
VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms for transformational human experiences, has received permission from Health Canada to manufacture and distribute additional psychedelic substances, most... Read more
Luff Enterprises Announces Final Health Canada License Approval for the NG Biomed Group of Companies
July 29, 2022
About Luff Enterprises Ltd. LUFF is a hemp and wellness company, focused on providing premium quality, innovative products across the United States through its online store. Committed to plant-based science, LUFF produces and sources a suite of thoughtfully designed products to benefit a wide range of user needs. Currently,... Read more
Zollaris Laboratories Corp. Receives Health Canada authorization to investigate PSILOCYBIN (PSYCHEDELIC MUSHROOMS) for potential new therapeutics
February 16, 2022
Ryan Allway February 16th, 2022 Psychedelics, Top News Psilocybin therapy is being investigated by Zollaris for the treatment of mental health and other unmet medical needs HAWKESBURY PROVIDENCE, Ontario, Feb. 16, 2022 /PRNewswire-PRWeb/ — Zollaris Laboratories Corporation. (hereafter, “Zollaris”) receives authorization from the Health Canada, Office of Controlled Substances for analytical investigation of several... Read more
Optimi Health Approved to Supply Psilocybin Under Health Canada’s Special Access Program
February 16, 2022
VANCOUVER, BC (GLOBE NEWSWIRE – February 16, 2022) — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to report that Health Canada has added the... Read more
Filament Health Announces Health Canada Approval For Phase II Trial Administering New Psilocybin Microdose Formulation
January 4, 2022
Ryan Allway January 4th, 2022 Psychedelics The clinical trial at the University of Toronto will study low doses of psilocybin in healthy subjectswith persistent depressive disorder VANCOUVER, BC, Jan. 4, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced... Read more
Canntab Receives Medical Sales Licence from Health Canada
November 11, 2021
Ryan Allway November 11th, 2021 TORONTO, Nov. 11, 2021 /CNW/ – Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the “Company” or “Canntab”), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it has received its medical sales license from Health Canada... Read more
